Search Results

There are 5737 results for: content related to: Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

  1. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Version of Record online : 8 APR 2014, DOI: 10.1111/ajco.12200

  2. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 987–994, R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin and L. Fearfield

    Version of Record online : 29 OCT 2012, DOI: 10.1111/bjd.12010

  3. Vemurafenib-Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma

    Pediatric Dermatology

    Volume 32, Issue 1, January/February 2015, Pages: 153–154, Emily S. West, Victoria L. Williams and Joseph G. Morelli

    Version of Record online : 6 MAR 2014, DOI: 10.1111/pde.12316

  4. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  5. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation

    The Journal of Dermatology

    Volume 42, Issue 9, September 2015, Pages: 881–888, Mi Ryung Roh, Jung Min Kim, Sang Hee Lee, Hong Sun Jang, Kyu Hyun Park, Kee Yang Chung and Sun Young Rha

    Version of Record online : 5 JUN 2015, DOI: 10.1111/1346-8138.12950

  6. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

    British Journal of Dermatology

    Volume 173, Issue 4, October 2015, Pages: 1024–1031, R. Sinha, J. Larkin, M. Gore and L. Fearfield

    Version of Record online : 11 OCT 2015, DOI: 10.1111/bjd.13958

  7. Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 9, September 2015, Pages: 1797–1806, R. Mössner, L. Zimmer, C. Berking, C. Hoeller, C. Loquai, E. Richtig, K.C. Kähler, J.C. Hassel, R. Gutzmer and S. Ugurel

    Version of Record online : 6 MAR 2015, DOI: 10.1111/jdv.13039

  8. You have full text access to this OnlineOpen article
    Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

    Cancer Medicine

    Volume 4, Issue 8, August 2015, Pages: 1205–1213, Geoffrey T. Gibney, Geneviève Gauthier, Charles Ayas, Philip Galebach, Eric Q. Wu, Sarang Abhyankar, Carolina Reyes, Annie Guérin and Yeun Mi Yim

    Version of Record online : 20 MAY 2015, DOI: 10.1002/cam4.475

  9. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

    Journal of Cutaneous Pathology

    Volume 41, Issue 6, June 2014, Pages: 539–543, Inbal Braunstein, Tara C. Gangadhar, Rosalie Elenitsas and Emily Y. Chu

    Version of Record online : 11 MAR 2014, DOI: 10.1111/cup.12318

  10. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 2, February 2015, Pages: 392–393, A. Chaminade, H. Conte, T. Jouary, A. Fauconneau, A.-S. Darrigade, M. Beylot-Barry and A. Pham-Ledard

    Version of Record online : 17 FEB 2014, DOI: 10.1111/jdv.12397

  11. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma

    Journal of Cutaneous Pathology

    Volume 41, Issue 7, July 2014, Pages: 568–575, Kari E. Sufficool, Donna M. Hepper, Gerald P. Linette, Eva A. Hurst, Dongsi Lu, Anne C. Lind and Lynn A. Cornelius

    Version of Record online : 29 APR 2014, DOI: 10.1111/cup.12346

  12. You have free access to this content
    Society for Melanoma Research 2014 Congress

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1169–1241,

    Version of Record online : 23 OCT 2014, DOI: 10.1111/pcmr.12317

  13. You have free access to this content
    Society for Melanoma Research 2013 Congress

    Pigment Cell & Melanoma Research

    Volume 26, Issue 6, November 2013, Pages: 932–1019,

    Version of Record online : 24 OCT 2013, DOI: 10.1111/pcmr.12166

  14. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Version of Record online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  15. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?

    International Journal of Rheumatic Diseases

    Taner Babacan, Ibrahim Halil Türkbeyler, Ozan Balakan, Yavuz Pehlivan, Ali Suner and Bunyamin Kısacık

    Version of Record online : 12 MAY 2014, DOI: 10.1111/1756-185X.12396

  16. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

    British Journal of Dermatology

    Volume 171, Issue 6, December 2014, Pages: 1529–1532, C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau, S. Allouche and L. Verneuil

    Version of Record online : 9 NOV 2014, DOI: 10.1111/bjd.13300

  17. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks

    British Journal of Dermatology

    Volume 172, Issue 1, January 2015, Pages: 239–243, R. Anforth, G. Carlos, A. Clements, R. Kefford and P. Fernandez-Peñas

    Version of Record online : 21 NOV 2014, DOI: 10.1111/bjd.13200

  18. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Version of Record online : 2 FEB 2015, DOI: 10.1002/prp2.113

  19. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma

    Journal of Cutaneous Pathology

    Volume 41, Issue 3, March 2014, Pages: 326–328, Penvadee Pattanaprichakul, Michael T. Tetzlaff, Whitney J. Lapolla, Carlos A. Torres-Cabala, Madeleine Duvic, Victor G. Prieto, Kenneth Y. Tsai and Jonathan L. Curry

    Version of Record online : 24 DEC 2013, DOI: 10.1111/cup.12273

  20. Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

    Pigment Cell & Melanoma Research

    Volume 28, Issue 3, May 2015, Pages: 318–323, Marlous Hoogstraat, Christa G. Gadellaa-van Hooijdonk, Inge Ubink, Nicolle J. M. Besselink, Mark Pieterse, Wouter Veldhuis, Marijn van Stralen, Eelco F. J. Meijer, Stefan M. Willems, Michael A. Hadders, Thomas Kuilman, Oscar Krijgsman, Daniel S. Peeper, Marco J. Koudijs, Edwin Cuppen, Emile E. Voest and Martijn P. Lolkema

    Version of Record online : 7 JAN 2015, DOI: 10.1111/pcmr.12347